- Visibility 522 Views
- Downloads 474 Downloads
- Permissions
- DOI 10.18231/j.ijos.2025.020
-
CrossMark
Study of functional outcome and complications of total hip replacement in avascular necrosis of femoral head due to sickle cell disease
- Author Details:
-
Sparsh Jain
-
Pradeep Choudhari
-
Sourabh Khande *
Sparsh Jain
Pradeep Choudhari
Background: Sickle cell disease (SCD) is an autosomal recessive genetic disorder marked by the production of abnormal sickle hemoglobin, which reduces red blood cell pliability. This results in vascular occlusion, leading to tissue ischemia and infarction. Bone involvement is a common manifestation, ranging from acute vaso-occlusive crises to chronic complications such as avascular necrosis (AVN). AVN of the femoral head frequently progresses to hip osteoarthritis, severely affecting joint function. Total hip replacement (THR) can significantly improve pain and mobility. This study evaluates the functional outcomes and complications of THR in patients with SCD.
Methodology: A total of 25 patients with SCD underwent THR. Functional outcomes were assessed using the Harris Hip Score (HHS) at 6-week, 3-month, and 6-month follow-ups.
Results: The mean age of patients was 26.80?±?9.35 years. The mean preoperative HHS was 58.25?±?4.32, which improved to 90.33?±?4.44 at 6 months postoperatively. At the 6-month follow-up, 15 patients (62.5%) showed excellent outcomes, 8 patients (33.3%) had good outcomes, and 1 patient (4.2%) had a fair result. Complications included limb length discrepancy in 3 patients (12%), dislocation in 2 patients (8%), superficial infection in 2 patients (8%), and 1 postoperative death (4%).
Conclusion: Total hip arthroplasty is an effective and reliable treatment for AVN of the hip secondary to sickle cell anemia. It significantly reduces pain, restores function, and enhances quality of life in affected patients.
Keywords: Sickle cell disease, Total hip arthroplasty, Avascular necrosis of femoral head.
References
- Hernigou P, Zilber S, Filippini P, Mathieu G, Poignard A, Galacteros F. Total THA in adult osteonecrosis related to sickle cell disease. Clin Orthop Relat Res. 2008;466(2):300–8.
- Acurio MT, Friedman RJ. Hip arthroplasty in patients with sickle- cell haemoglobinopathy. J Bone Joint Surg Br. 1992;74-B(3):367–
- Azam MQ, Sadat-Ali M. Quality of life in sickle cell patients after cementless total hip arthroplasty. J Arthroplasty. 2016;31(11):2536–
- Jones CA, Beaupre LA, Johnston DW, Suarez-Almazor ME. Total joint arthroplasties: current concepts of patient outcomes after surgery. Rheum Dis Clin North Am. 2007;33(1):71–86
- Vincent HK, Weng JP, Vincent KR. Effect of Obesity on inpatient rehabilitation outcomes after total hip arthroplasty. Obesity. 2007;15(2):522–30.
- Jan MH, Hung JY, Lin JC, Wang SF, Liu TK, Tang PF. Effects of a home program on strength walking speed and function after total hip replacement. Arch Phys Med Rehabil. 2004;85(12):1943–51
- Schwartz FH, Lange J. Factors that affect outcome following total joint arthroplasty: a review of the recent literature. Curr Rev Musculoskelet Med. 2017;10(3):346–55.
- Dore NK, Gopi M, Devadoss S, Devadoss A. Functional outcome in patients who have underwent Total Hip Replacement through modified lateral approach for various indications. Int J Orthop Sci. 2017;3(3):161–4.
- Hickman JM, Lachiewicz PF. Results and complications of total hip arthroplasties in patients with sickle-cell hemoglobinopathies. J Arthroplasty, 1997;12(4):420–5.
- Hernigou P, Housset V, Pariat J, Dubory A, Flouzat Lachaniette CH. Total hip arthroplasty for sickle cell osteonecrosis: guidelines for perioperative management. EFORT Open Rev. 2020;5(10):641–51.
- Issa K, Naziri Q, Maheshwari AV, Rasquinha VJ, Delanois RE, Mont MA. Excellent results and minimal complications of total hip arthroplasty in sickle cell hemoglobinopathy at mid-term follow-up using cementless prosthetic components. J Arthroplasty. 2013;28(9):1693–8.
- Farook MZ, Awogbade M, Somasundaram K, Reichert ILH, Li PLS. Total hip arthroplasty in osteonecrosis secondary to sickle cell disease. Int Orthop. 2019;43(2):293–8.
- Kenanidis E, Kapriniotis K, Anagnostis P, Potoupnis M, Christofilopoulos P, Tsiridis E. Total hip arthroplasty in sickle cell disease: a systematic review. EFORT Open Rev. 2020;5(3):180–8.
- Perfetti DC, Boylan MR, Naziri Q, Khanuja HS, Urban WP. Does sickle cell disease increase risk of adverse outcomes following total hip and knee arthroplasty? A nationwide database study. J Arthroplasty. 2015;30(4):547–51.
- Gulati Y, Sharma M, Bharti B, Bahl V, Bohra I, Goswani A. Short term results of cementless total hip arthroplasty in sicklers. Indian J Orthop. 2015;49(4):447–51. 102 Jain et al. / Indian Journal of Orthopaedics Surgery 2025;11(2):97–102
- Ilyas I, Alrumaih HA, Rabbani S. Noncemented Total Hip Arthroplasty in Sickle-Cell Disease: Long-Term Results. J Arthroplasty. 2018;33(2):477–81.